Kanata Bio

Profile

Over 30% of organ transplant patients have complications due to CMV. Kanata Bio is developing a CMV vaccine for organ transplantation. It has an option to license the asset from private equity firm that acquired VBI Vaccine assets. It is a Phase 2a asset, has an open IND and has already been dosed in 50 humans for glioblastoma. It is looking for partners during Bio Europe.

Kanata Bio logo
kanatabio.com

Contact

Event details

Date: November 9 - 11, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

25 in total
  • 20/20 OptimEyes Technologies
    20/20 OptimEyes Technologies is developing OPT-101, a sustained-release glaucoma eye drop designed to reduce…
  • Acanthus Pharma Services Inc.
    APS Pharma™ is a Canadian innovation-focused specialty chemistry…
  • AlloWide Health
    AlloWide Health is an Ontario-based biotechnology company developing innovative solutions to improve the…
  • Altis Labs
    Altis Labs is the AI endpoint company accelerating clinical trials. Altis has trained proprietary…
  • BioBackers
    Lumerate’s investor intelligence brand, tracks global life science deal flow to reveal behavioral signals that…
  • BioScript Solutions
    BioScript Solutions is a Canadian healthcare company committed to simplifying access to specialty care. BioScript…
  • Bough Bioscience
    Bough Bio is a pre-clinical stage company focused on decoding the molecular biology of senescent cells to unlock…
  • Dalriada
    Dalriada is a Canadian small molecule discovery company focusing on unlocking challenging and undruggable targets…
  • Intrepid Labs
    Drug formulation has the power to transform promising compounds into life-saving therapies, yet this step is…
  • JN Nova Pharma
    JN Nova Pharma is a Canadian biotechnology company developing a proprietary platform technology to…
  • Kanata Bio
    Over 30% of organ transplant patients have complications due to CMV. Kanata…
  • Medicenna Therapeutics
    Medicenna Therapeutics is a clinical-stage immunotherapy company engineering next-generation cytokine therapies…
  • Pattern Pharma Inc.
    Pattern’s patented PPI-100 activates innate immunity against cancers…
  • PlantForm Corporation
    PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead…
  • Q&C Services
    Q&C Services is Canada’s largest independent full-service consultant and importer for pharmaceutical, natural…
  • QurCan Therapeutics
    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS…
  • Rhythm Biotherapeutics Inc.
    Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation…
  • Singularity Pharma
    Singularity Pharma is a drug discovery business developing novel therapeutics for…
  • Specific Biologics
    Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class…
  • Spiderwort Biotechnologies
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • TheraVac Biologics
    TheraVac Biologics is a late-stage preclinical company developing innovative immunotherapies for…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…
  • Virano Therapeutics
    Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the…
  • YYZ Pharmatech Inc.
    YYZ Pharmatech Inc. (YYZ) is a deep tech company endeavoring to profoundly progress new medicine for…